

# The Pipeline and Future of Drug Development in Schizophrenia

**John A. Gray<sup>1</sup> and Bryan L. Roth<sup>2</sup>**

<sup>1</sup>Department of Psychiatry, University of California, San Francisco

<sup>2</sup>Department of Pharmacology, University of North Carolina

Addresses of Authors:

Bryan L. Roth MD, PhD

University of North Carolina School of Medicine

Department of Pharmacology

8032 Burnett-Womack, CB # 7365

Chapel Hill, NC 27599-7365

[bryan\\_roth@med.unc.edu](mailto:bryan_roth@med.unc.edu)

Phone 919-966-7535

Fax 919-966-5640

John A. Gray MD, PhD

University of California, San Francisco

Department of Psychiatry

401 Parnassus Ave, Box R-0984

San Francisco, CA 94143-0984

[jgray@lppi.ucsf.edu](mailto:jgray@lppi.ucsf.edu)

Phone 415-476-7000

Fax 415-476-7722

Corresponding author: John A. Gray

Running Title: The Drug Discovery Pipeline in Schizophrenia

Keywords: antipsychotics, cognition, negative symptoms, drug discovery, clinical trials, preclinical models, target validation

## **Abstract**

While the current antipsychotic medications have profoundly impacted the treatment of schizophrenia over the past 50 years, the newer atypical antipsychotics have not fulfilled initial expectations, and enormous challenges remain in long-term treatment of this debilitating disease. In particular, improved treatment of the negative symptoms and cognitive dysfunction in schizophrenia which greatly impact overall morbidity is needed. In this review we will briefly discuss the current pipeline of drugs for schizophrenia, outlining many of the strategies and targets currently under investigation for the development of new schizophrenia drugs. Many of these compounds have great potential as augmenting agents in the treatment of negative symptoms of cognition. In addition, we will highlight the importance of developing new paradigms for drug discovery in schizophrenia and call for an increased role of academic scientists in discovering and validating novel drug targets. Indeed, recent breakthroughs in genetic studies of schizophrenia are allowing for the development of hypothesis-driven approaches for discovering possible disease-modifying drugs for schizophrenia. Thus, this is an exciting and pivotal time for the development of truly novel approaches to drug development and treatment of complex disorders like schizophrenia.

## Introduction

Since the discovery of the antipsychotic effect of chlorpromazine more than 50 years ago<sup>1</sup>, the number of antipsychotic medications available for the treatment of schizophrenia has tremendously increased. With the development of the first generation antipsychotics, or typical antipsychotics, it was for the first time possible to treat the “positive” symptoms of schizophrenia, such as delusions and hallucinations, leading to the deinstitutionalization of the world’s mentally ill. The typical antipsychotic drugs are generally not thought to be effective at treating the “negative” symptoms, such as anhedonia and lack of motivation, and cognitive dysfunction of schizophrenia and have a high burden of extrapyramidal side effects (EPS)<sup>2</sup>.

The reintroduction of clozapine in the United States in 1989, issued in the current era of atypical or second generation antipsychotics. Atypical antipsychotic drugs are differentiated from typical antipsychotic drugs by virtue of a relative lack of EPS and serum prolactin elevation as compared with typical antipsychotic drugs. Clozapine itself has become the ‘gold standard’ antipsychotic medication because of its absence of debilitating extrapyramidal side-effects and its demonstrated clinical superiority in treatment-resistant schizophrenia<sup>3</sup> and suicidality<sup>4</sup>. Whether clozapine has any significant beneficial effect on negative symptoms and cognition is unclear<sup>2,5</sup>. Clozapine, however, is associated with its own set of serious side-effects including weight gain, diabetes and an increased risk of seizures and agranulocytosis<sup>6</sup>.

The documented superiority of clozapine<sup>3,7</sup> over other antipsychotic drugs has led to an intense effort over the past 15-20 years to develop clozapine-like atypical antipsychotics that are safer and better tolerated than clozapine. As such, multiple atypical and pseudo-atypical antipsychotic drugs, including risperidone, olanzapine, quetiapine and ziprasidone have been developed. Expectations that these agents comprised a breakthrough in the treatment of schizophrenia, especially with regards to improvements in negative symptoms and cognition were initially high<sup>8</sup>. These expectations, however, have not been realized<sup>9,10</sup>. While there is evidence that most of the new medications offer, at best, modest advantages over the typical antipsychotic drugs with regard to improvement in negative symptoms, cognitive impairment and functional capacity, the improvements are not consistent among studies<sup>2,11,12</sup>. In addition, the atypical antipsychotics carry their own substantial side effect burden, specifically weight gain and the metabolic syndrome<sup>13,14</sup>.

While the introduction of antipsychotic medications has had a profound effect on the treatment of schizophrenia over the past 50 years, and the atypical antipsychotic drugs have provided a larger and more diverse armamentarium of treatment options, the advances that have been made since the discovery of the antipsychotic properties of chlorpromazine have been small and incremental. Thus, enormous challenges remain in long-term treatment of this debilitating disease and continuing with the current paradigms of drug discovery is unlikely to produce significant advances<sup>15,16</sup>. It is therefore important to continue pursue diverse molecular targets for discovering new

antipsychotic compounds and to devise novel paradigms for drug discovery in schizophrenia.

A fundamental barrier to the discovery and development of novel treatments for schizophrenia remains that our level of understanding of the biological processes involved in schizophrenia is not sufficient to predict the therapeutic value of novel drug targets<sup>16</sup>. Thus, unvalidated targets are frequently left unpursued by the pharmaceutical industry and, frequently, companies have focused on alterations of existing medications (i.e. separating enantiomers or marketing active metabolites; e.g. 9-OH-risperidone or paliperidone)<sup>17</sup>, finding additional compounds that hit known and validated targets (“me too” drugs; e.g. ORG-5222 or asenapine)<sup>18</sup>, and on gaining approval on new indications for already marketed drugs<sup>19</sup> (e.g. clozapine for suicide in schizophrenia<sup>4</sup>). These methods, however, cannot continue indefinitely as the number of such possibilities is limited and thus it is critical to find new approaches to drug development. Interestingly, many of the atypicals will soon be going off patent, beginning with the launch of generic risperidone in 2007. Thus, there is significant interest and urgency within the pharmaceutical industry and among schizophrenia basic scientists and clinicians in developing safer and more-effective treatments for schizophrenia.

In this review we will briefly discuss the current pipeline of drugs for schizophrenia (Table 1) and will outline many of the strategies and targets currently under investigation for the development of new schizophrenia drugs. In addition, we will highlight the importance of developing new paradigms for drug discovery in

schizophrenia and call for an increased role of academic scientists in discovering and validating novel drug targets<sup>15,16</sup>.

## **Symptom Domains in Schizophrenia**

It has been proposed that new therapeutics in schizophrenia should target narrower ranges of symptoms rather than to try to develop the perfect “monotherapy” for a complex disorder<sup>20</sup>. This proposal is grounded in the complexity of schizophrenia which is characterized by severe and variable symptoms in a number of symptom domains, including positive symptoms such as hallucinations, delusions, and disorganized thought, negative symptoms such as a lack of motivation and interest, and a blunted affective range, and symptoms of cognitive impairments in attention, working memory, and a variety of executive functions. All of the currently approved drugs for the treatment of schizophrenia, however, were developed and are most efficacious at treating the positive symptoms of the disease while the negative symptoms and cognitive impairments actually contribute disproportionately more to the long-term disability in patients with schizophrenia<sup>21</sup>.

It is clear that patients who exhibit significant negative symptoms have particularly poor function capacity and quality of life<sup>22,23</sup> and while there was optimism that the atypicals comprised a breakthrough in the treatment of negative symptoms<sup>8</sup>, this prospect has not been realized to a clinically significant degree<sup>9,10</sup>. Despite the

limitations of current medications and the morbidity associated with negative symptoms, no drug has received Food and Drug Administration (FDA) approval for an indication of negative symptoms. As such, the National Institutes of Mental Health (NIMH) has recently released a consensus statement on the negative symptoms of schizophrenia<sup>24</sup> highlighting that negative symptoms represent a distinct and clinically important entity that should be a focus of future drug development efforts.

In addition to negative symptoms, schizophrenia is also characterized by significant cognitive impairments. For example, patients with schizophrenia have been documented to have problems with attention, working memory and learning and a variety of executive-level functions including abstract thinking and problem solving<sup>25,26</sup>. Indeed, a meta-analysis of cognitive deficits suggested that indices of cognitive deficits are much better predictors of functional outcome than indices from any other symptom domain<sup>27</sup>. However, these cognitive deficits have been relatively unimproved by currently approved antipsychotic drugs, though some evidence exists for the superiority of atypicals such as olanzapine and risperidone over typicals<sup>5,28,29</sup>. Due to the remaining need for improved treatment of the cognitive impairments in schizophrenia the National Institutes of Mental Health (NIMH) has begun a joint academic and industry initiative termed MATRICS (Measurement and Treatment Research to Improve Cognition in Schizophrenia) to facilitate the development of better treatments targeted at cognition<sup>30</sup>.



Thus, while psychopharmacologic research in schizophrenia aims for the development of new antipsychotic drugs with a more rapid onset of action, lower risk of side effects and improved efficacy in the domains of negative and cognitive symptoms it is unlikely that a single drug will have the desired effect across all of these domains. Optimal treatment of schizophrenia in the near future will likely rely on polypharmacy with individualized treatment aimed at the multidimensional nature of this disorder.

### **Current Antipsychotics and Drugs in Phase III Clinical Trials**

There are a number of theories regarding the mechanism of action of antipsychotic drugs<sup>16,31,32</sup>, though the precise mechanism remains incompletely understood. Briefly, it is important that all of the currently approved antipsychotic drugs have at least some affinity for the dopamine D<sub>2</sub> receptor and for the typicals there is a strong correlation between the therapeutic doses and their binding affinity for D<sub>2</sub> receptors<sup>33,34</sup>. In addition, positron emission tomography (PET) studies have demonstrated that antipsychotic effects are associated with a striatal D<sub>2</sub> receptor occupancy of 65-70%<sup>35,36</sup> with occupancy levels greater than 80% associated with increased risk of EPS<sup>36</sup>. The basis of the “atypicality” of newer medications, likewise is incompletely understood, though a primary theory is the serotonin-dopamine antagonism theory<sup>37</sup> which posits that a higher ratio of serotonin 5-HT<sub>2A</sub> receptor affinity to dopamine D<sub>2</sub> receptor affinity explains the enhanced efficacy and reduced EPS burden seen with the atypicals. This hypothesis is consistent with the atypical features

of risperidone, olanzapine, quetiapine, ziprasidone and the recently approved paliperidone (9-OH-risperidone). A third class of antipsychotics are the dopamine partial agonists, with aripiprazole being the only one currently approved for clinical use<sup>32</sup>. It is thought that the relative lack of EPS seen with clinical use of aripiprazole is due to its functional selectivity at D<sub>2</sub> receptors protecting against excessive blockade of the D<sub>2</sub> system<sup>32,38,39</sup>. Thus, while the mechanism of action of currently available antipsychotics is not fully known, D<sub>2</sub> receptor occupancy (either by antagonism or functionally-selective agonism) is important for the treatment of the positive symptoms of schizophrenia with some modulation of this D<sub>2</sub> blockade, likely increased dopamine transmission in the cortex and hippocampus, being important for both why SGAs and aripiprazole have a reduced EPS burden and somewhat higher efficacy at treating negative symptoms and cognitive dysfunction<sup>40</sup>.

The drugs in the pipeline for the treatment of schizophrenia that are currently in Phase III clinical trials appear to have the same mechanism of action of already available agents. Asenapine (formerly known as ORG-5222; Organon/Pfizer; now discontinued from clinical development) and iloperidone (Titan Pharmaceuticals) are antagonists at D<sub>2</sub> and 5-HT<sub>2A</sub> and many other receptors (Table 2) and bifeprunox (Lundbeck/Solvay) is a D<sub>2</sub> partial agonist. An NDA has been submitted for bifeprunox for treatment of schizophrenia (<http://www.google.com/search?sourceid=navclient&ie=UTF-8&rls=DMUS,DMUS:2006-43,DMUS:en&q=bifeprunox+fda>). A novel medication bexarotene—a retinoid-X-receptor activator is currently listed as being in Phase III clinical trials as an add-on medication

for schizophrenia (<http://clinicaltrials.gov/ct/show/NCT00141947?order=6>) As such, with the possible exception of bexarotene, all compounds currently in Phase III clinical trials represent “me-too” drugs that are not significantly different from currently available medications, though there is some clinical benefit to having additional drugs available as individuals may have differential responses to medications and have varying tolerance to side effects. As these drugs will not represent significant advances in the treatment of schizophrenia, this review will focus primarily on compounds at earlier stages of development.

The current “gold standard” antipsychotic, clozapine, interestingly has relatively weak affinity for the D<sub>2</sub> dopamine receptors but has moderate to high affinity and antagonist/inverse agonist activity for many other neurotransmitter receptors, including other dopamine receptors (D<sub>1</sub>, D<sub>3</sub>, D<sub>4</sub>), various serotonin receptors (5-HT<sub>2A</sub>, 5-HT<sub>2C</sub>, 5-HT<sub>6</sub>, 5-HT<sub>7</sub>), muscarinic acetylcholine receptors (M<sub>1</sub>, M<sub>2</sub>, M<sub>3</sub>, M<sub>4</sub>, M<sub>5</sub>), and adrenergic receptors ( $\alpha_1$ ,  $\alpha_2$ )<sup>31</sup>. Additionally, clozapine’s active metabolite N-desmethyl-clozapine, is a potent partial agonist at dopamine<sup>41</sup> and muscarinic<sup>42,43</sup> receptors. This extremely complex pharmacological profile is thought to underlie both clozapine’s superior clinical efficacy and its spectrum of serious side effects<sup>3</sup>. As such, much effort in antipsychotic drug development over the past two decades has been to create clozapine-like drugs that bind to fewer targets and thus reduce the side effect burden by targeting only the appropriate receptors. As will be reviewed below, attempts thus far to target clozapine’s ‘magic receptor’, however, have been largely been unsuccessful. Indeed, it appears that the paradigm of ‘one-disease one-target’ that became the dominant approach in the

pharmaceutical industry with the advent of molecular biological techniques, while ideal from a scientific and practical perspective, may not be suitable for complex psychiatric diseases such as schizophrenia. In recent years, a number of authors have proposed that designing selectively non-selective drugs that interact with several molecular targets (coined 'magic shotguns')<sup>31</sup> will lead to more effective medications for a variety of complex disorders<sup>31,44,45</sup>.

We will briefly review the individual molecular targets that may have a role in these 'magic shotguns' or in a polypharmacy approach targeting the various clinical symptom domains of schizophrenia **[Figure 3 – Domains]**. Where available, references to key review articles are provided. In addition, we will highlight how selective compounds have generally been ineffective as monotherapy for schizophrenia. Indeed, many of the drugs in Phase I, Phase II and preclinical development for the treatment of schizophrenia represent a shift from targeting D<sub>2</sub> and 5-HT<sub>2A</sub> receptors to targeting to other monoaminergic receptors and other neurotransmitter receptors, however, though results in small clinical trials have generally been less than encouraging.

### **Additional Dopaminergic Approaches**

In addition to the key role of dopamine D<sub>2</sub> receptors in antipsychotic function, compounds selective for other dopamine receptors have been explored as potential treatments for schizophrenia.

### *Dopamine D<sub>1</sub> receptors*

Significant evidence exists for the importance of dopamine D<sub>1</sub> receptors in the pathophysiology of schizophrenia, particularly having a role in cognitive dysfunction<sup>46</sup>. In drug-naïve patients with schizophrenia, a decreased level of D<sub>1</sub> receptor-like binding in the prefrontal cortex on PET imaging was correlated with the severity of negative symptoms and cognitive dysfunction<sup>47</sup>. In addition, chronic blockade of D<sub>2</sub> receptors results in a down-regulation of D<sub>1</sub> receptors in the prefrontal cortex and consequently produces severe impairments in working memory in non-human primates<sup>48</sup>. This down-regulation of D<sub>1</sub> receptors may explain why long-term treatment with typical antipsychotic drugs may contribute to the cognitive dysfunction in schizophrenia. In fact, direct blockade of D<sub>1</sub> receptors with selective antagonists, predicted to have antipsychotic effects in early preclinical models, showed no antipsychotic efficacy in clinical trials and may have exacerbated symptoms in some patients<sup>49,50</sup>. Thus, current efforts are focused on a possible role of D<sub>1</sub> receptor agonists in treating the cognitive dysfunction in schizophrenia. Indeed, short-term administration of the D<sub>1</sub> selective agonist, ABT-431, reversed the cognitive deficits in monkeys treated chronically with a D<sub>2</sub> receptor antagonist<sup>48</sup>. Other studies have also shown cognitive enhancement with a partial agonist of the D<sub>1</sub> receptor and selective, full D<sub>1</sub> receptor agonists in non-human

primates<sup>51,52</sup>. Thus, novel compounds targeted at stimulating D<sub>1</sub> receptor signaling either directly or indirectly may be of immense value in treating cognitive deficits in schizophrenia, though some potential pitfalls may need to be overcome. First, in addition to insufficient D<sub>1</sub> receptor activity, excessive D<sub>1</sub> activity such as that resulting from acute stress may also be deleterious to cognition<sup>53</sup>. In addition, chronic treatment with a D<sub>1</sub> receptor agonist may actually lead to downregulation of the D<sub>1</sub> receptor potentially worsening cognition in the long-term. Thus, an optimized level of D<sub>1</sub> receptor activation may be required to realize full cognitive benefits<sup>53</sup>, which may be accomplished by partial agonists or an intermittent pattern of administration<sup>48,54</sup>.

### *Dopamine D<sub>3</sub> receptors*

D<sub>3</sub> receptors are structurally similar to D<sub>2</sub> receptors and thus most antipsychotics have relatively high affinity at this site<sup>55</sup>. As such, significant effort has been placed on investigating the potential role of the D<sub>3</sub> receptor as a target for drug development in schizophrenia. Indeed, a post-mortem study of drug-free patients with schizophrenia demonstrated elevated D<sub>3</sub> receptor levels in contrast to normal D<sub>3</sub> receptor levels in patients treated with antipsychotic medications<sup>56</sup>. In addition, a D<sub>3</sub> receptor partial agonist was able to block the increase in locomotor activity in mice induced by N-methyl-D-aspartate (NMDA) glutamate receptors antagonists, such as phencyclidine or ketamine, a frequently used preclinical model of psychosis<sup>57</sup>. As such, multiple selective dopamine D<sub>3</sub> agents are currently in clinical trials for the treatment of schizophrenia. For example, A-437203 is currently undergoing Phase II trials, although

clinical data are not yet available<sup>55</sup> as is SB-773812 (Clinical Trials @.gov identifier NCT00259870). Development of another agent, PNU-177864, which is a partial agonist at D<sub>3</sub> receptor appears to have been stopped due to safety concerns<sup>58</sup>. Thus, the potential antipsychotic efficacy of selective D<sub>3</sub> receptor agonism and antagonism remains unknown at this time, though some data suggests the benefit of D<sub>3</sub> receptor partial agonists in the treatment of Parkinson's disease and drug addiction<sup>59</sup>. Additional preclinical studies have also suggested a role of D<sub>3</sub> receptor antagonists in improving negative symptoms<sup>60</sup> and working memory<sup>61</sup>, though clinical evidence is unavailable.

#### *Dopamine D<sub>4</sub> receptors*

When the dopamine D<sub>4</sub> receptor was initially cloned it was also found that clozapine had higher affinity for this receptor than for D<sub>2</sub> receptors creating significant speculation that the D<sub>4</sub> receptor may be clozapine's "magic receptor"<sup>62</sup>. Further support of a role of D<sub>4</sub> receptors in schizophrenia came from postmortem studies showing higher levels of D<sub>4</sub> receptors in the forebrain, though these results have not been entirely consistent among studies<sup>63</sup>. Even so, clinical trials of D<sub>4</sub> antagonists have not demonstrated any appreciable efficacy in the treatment of acute schizophrenia. For example, randomized, controlled trials of L-745870 and sonopiprazole found no differences in clinical responses compared with placebo-treated patients with schizophrenia<sup>64,65</sup>. In addition, a trial of finanserin, a potent antagonist at both D<sub>4</sub> and serotonin 5-HT<sub>2A</sub> receptors, also found no evidence of antipsychotic efficacy versus placebo in patients with schizophrenia<sup>66</sup>. These clinical trial failures have suggested

that selective D<sub>4</sub> receptor antagonism alone is not responsible for the antipsychotic efficacy of clozapine; however, it is possible that D<sub>4</sub> receptor blockade in collaboration with action at other neurotransmitter receptors may be clinically beneficial. Indeed, studies of the physiological roles for the D<sub>4</sub> receptor are finding that D<sub>4</sub> receptors may play an important role in impulsivity and working memory<sup>63</sup>. For example, recent findings demonstrated that D<sub>4</sub> receptors in hippocampal neurons can decrease NMDA receptor activity<sup>67</sup> and inhibit glutamatergic signaling in the frontal cortex<sup>68</sup>. In addition, D<sub>4</sub> antagonists were observed to reverse phencyclidine-induced cognitive impairment in monkeys<sup>69</sup>, together suggesting a suggesting that D<sub>4</sub> receptor-selective agents may be valuable in the treatment of the cognitive deficits in schizophrenia.

### *Catechol-O-methyltransferase*

Catechol-O-methyltransferase (COMT) is a postsynaptic enzyme that methylates and thereby deactivates synaptically released catecholamines, particularly dopamine<sup>70</sup>. Historically, monoamine oxidase was considered the primary enzyme for the initial deactivation of synaptic dopamine<sup>71</sup>, though mounting evidence suggests that COMT may be especially important for the breakdown of dopamine, particularly in the prefrontal cortex<sup>72</sup>. For example, COMT knockout mice show increased baseline levels of dopamine, but not other catecholamines such as norepinephrine, specifically in the frontal cortex<sup>73</sup>. In addition, the COMT knockout mice also showed enhanced memory performance<sup>73</sup>, suggesting a potential role of COMT inhibition in improving cognition. Indeed, a selective, reversible inhibitor of COMT, tolcapone, has been reported to



improve working memory in rodents<sup>74</sup> and has been shown to improve cognitive dysfunction in patients with advanced Parkinson's disease<sup>75</sup>, though use is limited due to a risk of liver failure<sup>76</sup>. Other COMT inhibitors are currently being investigated for treatment of the cognitive dysfunction in schizophrenia.

Interestingly, a common single nucleotide polymorphism (SNP) in the gene encoding COMT (val108/158met) results in the transcription of a variant of the COMT enzyme with approximately 40% less enzymatic activity in humans<sup>77</sup>. The reduced activity associated with the met variant presumably results in greater availability of dopamine in the prefrontal cortex and, thus, may be linked to some aspects of cognition in humans. Furthermore, accumulating evidence predicts that patients with schizophrenia who have the met allele may have improved cognitive response to clozapine<sup>78</sup>. The potential of pharmacologic inhibition of COMT in the long-term treatment of the cognitive dysfunction in schizophrenia, however, remains to be determined.

## **Serotonergic Approaches**

As serotonin receptors have been postulated to play a critical role in the action of the atypical antipsychotic drugs, we will briefly review a few of the serotonin receptors that continue to be targets in drug development for schizophrenia.

### *Serotonin 5-HT<sub>2A</sub> receptors*

Since the report that the atypicals, as a group, bind with higher affinity to 5-HT<sub>2A</sub> receptors than to dopamine D<sub>2</sub> receptors<sup>79,80</sup>, selective 5-HT<sub>2A</sub> receptor antagonists have been extensively explored as putative antipsychotic drugs. Unfortunately, however, the 5-HT<sub>2A</sub> selective compound M-100907, was discontinued after two Phase III trials found M-100907, although more effective than placebo, failed to reduce symptoms to the same extent as haloperidol<sup>81</sup>. A phase 2 study of the 5-HT<sub>2A/2C</sub> antagonist SR46349B (eplivanserin) showed efficacy similar to haloperidol and better than placebo<sup>82</sup>. Thus, it is now clear that while selective 5-HT<sub>2A</sub> receptor antagonists may have antipsychotic properties, they are not superior to D<sub>2</sub> antagonists. It is likely that the predominant role of 5-HT<sub>2A</sub> receptors in antipsychotic action is to modulate dopaminergic tone, particularly along the mesocortical pathway<sup>83,84</sup>. However, these studies also provide insight into why compounds with more complex pharmacologic profiles are likely superior to the “magic bullet” approach in the treatment of complex diseases such as schizophrenia<sup>31,45</sup>.

### *Serotonin 5-HT<sub>1A</sub> receptors*

In addition to antagonism of the 5-HT<sub>2A</sub> receptor, the agonist effects of clozapine on 5-HT<sub>1A</sub> receptors have been postulated to contribute to its superior efficacy<sup>85</sup>. Research has also demonstrated that 5-HT<sub>1A</sub> receptor agonism may actually result from 5-HT<sub>2A</sub> receptor antagonism suggesting that 5-HT<sub>1A</sub> agonism alone may produce an

atypical antipsychotic drug when coupled with weak D<sub>2</sub> antagonism. Indeed, aripiprazole, a D<sub>2</sub> receptor partial agonist, may owe some of its atypical properties to its net effect of weak D<sub>2</sub> receptor antagonism, 5-HT<sub>2A</sub> receptor antagonism and 5-HT<sub>1A</sub> receptor agonism<sup>32,38,86</sup>. As such, 5-HT<sub>1A</sub> receptor modulation is most likely to play a role in regulating dopaminergic tone similarly to 5-HT<sub>2A</sub> receptors<sup>84</sup>, thus contributing to atypicality. Particularly, 5-HT<sub>1A</sub> receptor agonism has been suggested to enhance dopamine levels in the prefrontal cortex<sup>87</sup>, which may be related to the modest efficacy of many atypicals in treating the negative symptoms and cognitive dysfunction of schizophrenia. Thus far, attempts to develop medications combining 5-HT<sub>1A</sub> receptor agonism with other receptor binding activities have not fully replicated the superior clinical profile of clozapine, again highlighting the need for compounds with more complex pharmacologic profiles<sup>31</sup>.

#### *Serotonin 5-HT<sub>4</sub> receptors*

Serotonin 5-HT<sub>4</sub> receptors are found at high densities in the hippocampus, frontal cortex and amygdala, suggesting a role of these receptors in cognitive functions<sup>88</sup>. Indeed, 5-HT<sub>4</sub> receptors have been shown to be markedly decreased in patients with Alzheimer's disease<sup>89</sup>. 5-HT<sub>4</sub> receptor agonists have shown promise in the improvement of cognitive function by enhancing cholinergic transmission in the hippocampus<sup>88</sup>, thus are being developed for the treatment of Alzheimer's disease. Interestingly, a recent study showed that the activation of 5-HT<sub>4</sub> receptors in a neuronal culture inhibited the secretion of  $\beta$ -amyloid peptide and enhanced neuronal survival<sup>90</sup>.

While 5-HT<sub>4</sub> receptor-selective agonists are mostly being studied for their role in the treatment of Alzheimer's disease, they may also be of benefit in the treatment of the cognitive dysfunction in schizophrenia.

### *Serotonin 5-HT<sub>6</sub> receptors*

As several atypical antipsychotics, including clozapine and olanzapine exhibit high nanomolar affinity for 5-HT<sub>6</sub> receptors<sup>91</sup>, significant efforts have been made to understand its possible role in schizophrenia and other neuropsychiatric disorders<sup>92</sup>. Studies in rodents have suggested a role of the 5-HT<sub>6</sub> receptors in the control of cholinergic neurotransmission<sup>93</sup>, and the selective 5-HT<sub>6</sub> receptor antagonist SB-271046 has been shown to improve memory retention in the water maze test of spatial learning and memory<sup>94</sup>. Thus, 5-HT<sub>6</sub> receptors may have an important future role in the treatment of cognitive deficits in neuropsychiatric illnesses such as Alzheimer's disease and schizophrenia.

### **Other Monoaminergic Approaches**

#### *α<sub>2</sub> adrenergic receptors*

In the prefrontal cortex, α<sub>2</sub> adrenergic receptors appear to play an important role in cognitive functioning<sup>95</sup>. Indeed, treatment with the α<sub>2</sub> adrenergic receptor agonists

clonidine and guanfacine has been shown to improve cognitive performance in small trials of patients with schizophrenia<sup>96,97</sup>. In addition, patients randomized to risperidone plus guanfacine showed significant improvement on tasks of working memory and attention compared with patients receiving typical antipsychotics plus guanfacine<sup>97</sup>. Thus,  $\alpha_2$  adrenergic receptor activity is likely to be important in the development of new drugs for schizophrenia that can improve cognition. Complicating the picture, however, is the fact that clozapine and other atypicals have potent antagonist properties at  $\alpha_2$  adrenergic receptors<sup>98</sup>, which may contribute to the atypicality of atypicals by preferentially enhancing dopaminergic transmission in the frontal cortex over subcortical dopaminergic pathways<sup>99</sup>. Indeed, combined treatment of a selective  $\alpha_2$  adrenergic receptor antagonist with a typical antipsychotic drug has been reported to produce a profile of antipsychotic activity similar to clozapine<sup>100</sup>. Thus, balancing  $\alpha_2$  adrenergic receptor activity to achieve both antipsychotic and pro-cognitive efficacy may be challenging.

## **Cholinergic Approaches**

Acetylcholine is known to play an important role not only in motor function, but also in various domains of cognition, particularly attention, learning, and memory<sup>101</sup>. Indeed, cholinergic dysfunction has been shown to be central to the pathophysiology of Alzheimer's disease and has also been postulated to contribute to the cognitive deficits of various neuropsychiatric disorders, including schizophrenia<sup>102</sup>. Cholinesterase

inhibitors, such as donezepil and rivastigmine, are currently the main pharmacologic approach to the treatment of Alzheimer's disease and have been shown to slow the cognitive decline in this neurodegenerative disease<sup>103</sup>. As such, it has been proposed that cholinesterase inhibitors may also be useful in the treatment of the cognitive dysfunction in schizophrenia<sup>104</sup>. Indeed, there have been multiple small randomized controlled trials of cholinesterase inhibitors in patients with schizophrenia, though results have been disappointing<sup>105</sup>. In addition to cholinesterase inhibitors, significant efforts are underway to explore the modulation of various subtypes of both muscarinic and nicotinic acetylcholine receptors in the treatment of schizophrenia.

#### *Muscarinic acetylcholine receptors*

Of the five known muscarinic acetylcholine receptors (M<sub>1</sub>–M<sub>5</sub>), the M<sub>1</sub> receptor has been most closely linked to cognition and schizophrenia<sup>106</sup>. For example, decreased M<sub>1</sub> receptor binding has been reported in postmortem studies of the prefrontal cortex, hippocampus, and striatum from patients with schizophrenia<sup>106</sup>, suggesting that M<sub>1</sub> receptor agonism might be beneficial in treating the cognitive dysfunction in schizophrenia<sup>106</sup>. Indeed, the salutary actions of clozapine on cognition have been hypothesized to be due in part action at M<sub>1</sub> receptors<sup>107</sup>. However, studies have variably reported clozapine to be both an agonist and an antagonist at M<sub>1</sub> and other muscarinic receptors<sup>106</sup>. Interestingly, the major active metabolic of clozapine, N-desmethylclozapine, has been reported to be a potent M<sub>1</sub> agonist that preferentially binds to M<sub>1</sub> receptors versus clozapine<sup>108</sup> although more comprehensive studies fail to

demonstrate selectivity N-desmethylclozapine for M<sub>1</sub> receptors<sup>42</sup>. In addition, N-desmethylclozapine has high affinities for 5-HT<sub>2A</sub> and 5-HT<sub>2C</sub> receptors, and is a partial D<sub>2/3</sub> receptor agonist<sup>41,43</sup>, suggesting that this metabolite of clozapine may also have antipsychotic and cognition-enhancing properties. Indeed, N-desmethylclozapine (ACP-104) and other M<sub>1</sub> receptor agonists are in clinical trials as potential treatments of the cognitive dysfunction in schizophrenia. Xanomeline, a non-selective muscarinic agonist with potent actions at a variety of non-muscarinic GPCRs including 5-HT<sub>1A</sub> and 5-HT<sub>2A</sub> receptors<sup>109</sup> improved cognition and psychotic-like symptoms in Alzheimer's disease, but was discontinued due to poor tolerability<sup>110</sup>. The relatively non-selective actions of xanomeline at a number of GPCRs (<http://pdsp.med.unc.edu/pdsp.php>) should engender caution among schizophrenia researchers for embracing positive data from xanomeline studies as being specifically indicative of a role for M1 receptors in schizophrenia. Overall, evidence suggests M<sub>1</sub> receptor agonists could be useful in treating various symptom domains in schizophrenia, though the roles of the other muscarinic receptor subtypes are less clear.

### *Nicotinic acetylcholine receptors*

It is well known that the smoking rates in individuals with schizophrenia are significantly higher than in the general population and some have suggested that these individuals may be 'self-medicating' with nicotine<sup>111</sup>. Indeed, nicotine administration has been shown to improve various measures of cognition may ease some of the side effects of antipsychotic medications<sup>111</sup>. Thus, considerable research has explored the

potential use of nicotinic agents for the treatment of schizophrenia, specifically selective agonists and antagonists at various subunits of the nicotinic acetylcholine receptor. For example, the  $\alpha 7$  nicotinic receptor subtype modulates auditory gating, a process known to be deficient in schizophrenia<sup>112</sup> and agonists at  $\alpha 7$  receptors such as 3-2,4-dimethoxybenzylidene anabaseine (DMXB-A) can normalize the auditory gating deficits in rodents<sup>113</sup>. Moreover, DMXB-A had a positive effect on a cognitive battery in a small proof-of-concept trial in humans<sup>114</sup>, and additional clinical trials of  $\alpha 7$  receptor agonists are underway. However, long-term use of  $\alpha 7$  agonists may induce the desensitization of nicotinic receptors, leading to a limited duration of efficacy<sup>112</sup>.

It has also been suggested that  $\alpha 4\beta 2$  nicotinic receptors are involved in cognition, and agonists of  $\alpha 4\beta 2$  receptors such as RJR 2403 can produce significant and long-lasting improvement of memory in rats<sup>115</sup>. Thus, nicotinic  $\alpha 4\beta 2$  receptor agonists may be of therapeutic benefit for the treatment of the cognitive deficits in schizophrenia. In addition, allosteric modulators of nicotinic receptors are being explored as therapeutic agents. For example, galantamine is a positive allosteric modulator of nicotinic receptors in addition to being an acetylcholinesterase inhibitor<sup>112</sup>. The allosteric interaction of galantamine with nicotinic receptors can enhance the channel activity induced by a receptor agonist, either endogenous acetylcholine or theoretically a coadministered subtype-selective agonist.

## **Glutamatergic Approaches**



Since the 1950s, the *N*-methyl-D-aspartate (NMDA) glutamate receptor antagonists phencyclidine (PCP) and ketamine were known to produce a large range of schizophrenia-like symptoms including psychotic symptoms, negative symptoms and cognitive dysfunction<sup>116</sup>. Thus, it has been hypothesized for decades that some deficiency in NMDA function might play a role in the pathophysiology of schizophrenia<sup>116</sup>, suggesting that drugs that can augment NMDA receptor activity may have therapeutic potential in schizophrenia. It is also important to note, that a competing hypothesis suggests that a hyperactivity of glutamatergic neurotransmission is involved in the psychopathology of schizophrenia, leading to seemingly contradictory pharmacologic approaches being explored<sup>116</sup>. Below, we briefly review various approaches being explored for modulating NMDA receptor neurotransmission and discuss approaches aimed at other glutamatergic mediators.

### *NMDA glutamate receptors*

NMDA glutamate receptors are ligand-gated ion channels with a primary glutamate binding site and an allosteric glycine binding site<sup>116</sup>. Interestingly, the opening of the NMDA channel appears to require both glutamate and glycine binding and can be modulated by multiple substances, including  $Mg^{2+}$ , polyamines, and protons, at various allosteric sites<sup>116</sup>. Thus, there are multiple potential sites to target for enhancing NMDA receptor activity; however, direct agonists of the glutamate binding site of the NMDA receptor may not be clinically feasible due to the risk of excess

excitation causing neurotoxicity and seizures. Therefore, the allosteric sites on the NMDA receptor complex, particularly the glycine binding site have been targeted for development of pharmacotherapy in schizophrenia.

Compounds that target the glycine site of the NMDA receptor complex have been studied in multiple small clinical trials and include the amino acids glycine, D-cycloserine, D-serine and D-alanine<sup>117</sup>. In most of these studies, the test compound was administered along with either a typical or atypical antipsychotic, and there appears to be significant benefits reducing negative symptoms and cognitive impairment in patients with schizophrenia<sup>117</sup>. Of the four agents, D-cycloserine has been the least efficacious, likely due to it being a partial agonist that acts as an antagonist at high doses. Interestingly, when used concurrently with clozapine, glycine<sup>118</sup> and D-serine<sup>119</sup> have been reported to be ineffective while D-cycloserine seemed to worsen symptoms<sup>120</sup>, possibly because clozapine may already enhance glycine and glutamate neurotransmission. Overall, agonists at the glycine allosteric site of the NMDA glutamate receptor hold promise in the treatment of the negative and cognitive symptoms of schizophrenia, possibly as an augmentation of currently existing antipsychotics.

### *Glycine transporter*

Another strategy being explored to boost NMDA activity at the glycine allosteric site is to increase synaptic glycine by inhibiting the glycine transporter. The use of

glycine transport inhibitors would have the advantage of avoiding the very high doses of glycine and D-serine that are needed. Indeed, preclinical data suggest that inhibition of glycine reuptake represents a feasible approach to enhance NMDA receptor activity and possibly be therapeutic in schizophrenia<sup>116</sup>. For example, selective, high-affinity inhibitors of the glycine transporter, including Org-24598<sup>121</sup>, N-[3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)propyl]sarcosine<sup>122</sup> and SSR-504734 have been found to reverse PCP-induced hyperactivity and dopaminergic hyperreactivity in rodents<sup>121,122</sup>. Clinical trials to date, however, have only studied the low potency glycine transport inhibitor sarcosine (N-methyl glycine). In a clinical trial of sarcosine added to the stable antipsychotic regimen of patient with schizophrenia, there was a highly significant reduction in negative symptoms, along with smaller but significant reductions in positive and cognitive symptoms<sup>123</sup>. Interestingly, a subsequent study with patients on clozapine, found no improvement of symptoms with the addition of sarcosine, a result similar to studies with the NMDA glycine site agonists<sup>124</sup>. These results strongly suggest a role of glycine transport inhibitors in the treatment of schizophrenia, though results of trials with selective, high-potency inhibitors are anticipated.

### *Metabotropic glutamate receptors*

Agents acting at metabotropic glutamate receptors (mGluR) are currently in preclinical development. Specifically, there are two main groups of mGluRs being studied in schizophrenia, Group I receptors include mGluR1 and mGluR5 and Group II receptors include mGluR2 and mGluR3<sup>125</sup>. Group I receptors increase presynaptic

glutamate release while Group II receptors inhibit presynaptic glutamate release, however agonists at each are being explored as potential treatments in schizophrenia demonstrating the duality of glutamatergic hypotheses in the pathophysiology of schizophrenia<sup>126,127</sup>. Indeed, both approaches have shown efficacy in preclinical models of schizophrenia<sup>116</sup>, however, development of selective agents at mGluR subtypes has been an issue. Allosteric modulators of mGluRs hold promise as therapeutic agents and indeed, several groups have recently developed highly selective allosteric potentiators of these receptors<sup>127,128</sup>. These selective allosteric modulators of mGluRs compounds may prove beneficial in the treatment of schizophrenia and preliminary positive results with an mGluR2 agonist in Phase II trials have been reported ([http://www.prnewswire.com/cgi-bin/micro\\_stories.pl?ACCT=916306&TICK=LLY&STORY=/www/story/12-07-2006/0004487009&EDATE=Dec+7,+2006](http://www.prnewswire.com/cgi-bin/micro_stories.pl?ACCT=916306&TICK=LLY&STORY=/www/story/12-07-2006/0004487009&EDATE=Dec+7,+2006)).

#### *Other ionotropic glutamate receptors*

Another glutamatergic approach to drug development in schizophrenia has been the development of compounds that stimulate AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) and kainate glutamate receptors. AMPA receptors help to activate NMDA receptors while NMDA receptors are required for proper incorporation of AMPA receptors into the postsynaptic membrane, a process involved in synaptic plasticity<sup>129</sup>. Indeed, administration of the AMPA/kainate receptor antagonist, LY-293558, partially reversed the impairment of working memory induced by subanesthetic

doses of ketamine in rats<sup>130</sup>. Further preclinical data suggest that AMPA/kainate receptor antagonists may have antipsychotic efficacy and possible utility in the treatment of cognitive deficits in schizophrenia, though further research is indicated<sup>40</sup>.

In apparent contrast to the postulated utility of AMPA/kainate receptor antagonists as antipsychotics, allosteric potentiators of AMPA receptor function, a class of compounds termed ampakines, are also being studied as potential treatments for schizophrenia<sup>129</sup>. Ampakines may avoid the desensitization frequently seen with direct AMPA agonists and can enhance glutamatergic transmission, facilitating long-term potentiation, learning and memory in rodents<sup>129</sup>. In a clinical trial of schizophrenia patients on clozapine, coadministration of the ampakine CX-516 yielded significant improvements in memory and attention<sup>131</sup>, however, a trial of CX-516 as monotherapy in schizophrenia showed no clear beneficial effects<sup>132</sup>. Importantly, higher potency ampakines are currently under clinical development as both monotherapy for schizophrenia and adjunctive treatment for cognitive dysfunction, though results of trials are not yet available. An initial trial with Org24448 has been planned for cognition enhancement in schizophrenia (NCT00425815) though progress has not yet been reported for this compound. Overall, it remains unclear if modulation of AMPA receptors by agonists, antagonists or allosteric modulators such as ampakines has therapeutic value in the treatment of schizophrenia although this is a highly active area of current research.

## Other Approaches

### *Cannabinoid receptors*

A recent meta-analysis demonstrated a statistically significant correlation of prior cannabis use and the development of schizophrenia<sup>133</sup>, adding to a large amount of evidence implicating the endogenous cannabinoid system in schizophrenia<sup>134</sup>. The endogenous cannabinoid system contains at least two cannabinoid receptors, the CB<sub>1</sub> and CB<sub>2</sub> receptors. A selective CB<sub>1</sub> receptor antagonist, SR-141716 showed activity in preclinical models of antipsychotic efficacy<sup>135,136</sup>, however, in a recent clinical trial, SR-141716 failed to antipsychotic efficacy versus placebo<sup>82</sup>. Whether further clinical trials with cannabinoid receptor antagonists in schizophrenia are warranted is debatable.

### *Neurokinin receptors*

Neurokinin 1 (NK<sub>1</sub>) and neurokinin 3 (NK<sub>3</sub>) receptors have been explored as potential targets for neuropsychiatric drug development<sup>137-139</sup>. NK<sub>1</sub> receptor antagonists may have efficacy in the treatment of depression, though a recent clinical trial of the NK<sub>1</sub>-selective antagonist, aprepitant, for depression did not show efficacy versus paroxetine<sup>140</sup>. NK<sub>3</sub> receptor antagonists, however, have been investigated as potential antipsychotic agents as NK<sub>3</sub> receptors appear to regulate midbrain dopaminergic function<sup>141</sup>. As such, several NK<sub>3</sub> receptor antagonists, including osanetant (Sanofi-Synthélabo) and talnetant (Glaxo Smith Kline), have been in development as potential

treatments for schizophrenia. In a recent clinical trial, osanetant showed statistically significant improvement in positive symptoms and global assessment versus placebo and was similar to haloperidol<sup>82</sup>, however an informal report of a follow-up study indicated negative results and the compound was discontinued<sup>141</sup>. No clinical trial data have been published to date talnetant and trials in schizophrenia appear to have been discontinued; thus whether NK<sub>3</sub> receptor antagonists may serve as novel antipsychotics either as monotherapy or as augmentation for the treatment of negative symptoms or cognition remains to be determined.

### *Neurotensin receptors*

Neurotensin (NT) is a neuropeptide that, for decades, has been implicated in the pathophysiology of schizophrenia as it is closely associated with, and modulates dopaminergic and other neurotransmitter systems<sup>142</sup>. Indeed, significant preclinical data suggested a potential use of NT receptor agonists as novel therapeutic agents for the treatment of schizophrenia<sup>142</sup>. For example, administration of NT agonists, such as PD-149163, can reverse amphetamine-induced effects on hyperactivity and prepulse inhibition without inducing catalepsy<sup>143</sup>. Thus, NT receptor agonists likely have potential in the treatment of schizophrenia; however, there have been no published clinical trials of NT agonists. Interestingly, there is also seemingly contradictory evidence indicating that neurotensin antagonists may have antipsychotic potential as there may be pathologically increased NT tone in schizophrenia<sup>142</sup>. A recent clinical trial, however, showed no antipsychotic efficacy of a potent and selective NT<sub>1</sub> receptor antagonist, SR-

48692, compared with placebo<sup>82</sup>. Thus, NT antagonists may not be useful for the treatment of schizophrenia; however, clinical trials of NT agonists are needed to explore this novel treatment strategy for schizophrenia.

### *Additional approaches*

A number of other approaches for the development of novel therapeutics for the treatment of schizophrenia have been described including, cyclooxygenase-2 (COX2) inhibitors, phosphodiesterase 10A (PDE10A) inhibitors, neurosteroids, and secretin. COX-2 inhibitors such as celecoxib have been hypothesized improve cognitive performance by reducing inflammatory processes in the central nervous system<sup>144</sup>. Indeed, in one small trial, there was some significant benefit with the addition of celecoxib to risperidone<sup>145</sup>. PDE10A is a recently identified phosphodiesterase expressed at high levels in the brain and PDE10A inhibitors have been shown to antagonize the effects of both amphetamine and phencyclidine in rodents suggesting antipsychotic potential<sup>146</sup>. Secretin is a gastrointestinal peptide that has poorly defined roles in the brain, however, recent studies have suggested a possible therapeutic benefit in autism and transient improvement of symptoms in schizophrenia<sup>147</sup>, though repeated intravenous administration is likely to limited therapeutic potential. Neurosteroids, such as dehydroepiandrosterone (DHEA) have been implicated in neuroprotection and enhancement of NMDA receptor neurotransmission suggesting therapeutic potential in schizophrenia<sup>40</sup>. Indeed, a double-blind study of DHEA as an adjunct to antipsychotic treatment in chronic schizophrenic patients with prominent



negative symptoms suggests some efficacy at improving negative symptoms, especially in women<sup>148</sup>, though further studies are needed.

## **Moving Towards the Future**

As is apparent from the preceding sections, most of the current strategies for developing novel compounds for the treatment of schizophrenia have not been successful. All currently available medications target D<sub>2</sub> dopamine receptors—a paradigm that has dominated drug development for the past 20 years—and many have been identified by activity in preclinical models that were devised based on pharmacologic manipulation (such as psychostimulant-induced behaviors). Indeed, these models have helped identify additional antagonists at dopamine D<sub>2</sub> and serotonin 5-HT<sub>2A</sub> receptors, and are helping to identify novel neurotransmitter approaches to modulate dopamine. In addition, the development of highly selective agents for various neurotransmitter receptor targets has been and will continue to be extremely valuable in the elucidation of brain physiology and understanding of the pathophysiology of complex disorders such as schizophrenia; however, future drug discovery approaches will have to be truly revolutionary and based on a better understanding of the pathogenesis of the disease. Interestingly, we are in an era of increased knowledge and enormous spending in biomedical research but a dearth of advances in therapeutics. This decrease in the introduction of fundamentally new drugs into clinical practice is evidence of attempts to make a fundamental shift in the basic paradigms

used for drug discovery. Thus, this is an exciting and pivotal time for the development of truly novel approaches to drug development and treatment of complex disorders like schizophrenia. Below, we will discuss some of the exciting advances in our understanding of the pathophysiology of schizophrenia, will highlight some novel strategies currently being explored for drug development, and will stress the need for and increased role of academic scientists in target identification and validation.

### *Models of the Pathophysiology of Schizophrenia*

A major critique of current drug discovery approaches for schizophrenia is that adequate treatments cannot be developed because the underlying causes of major mental illnesses remain incompletely understood<sup>21,31,149</sup>. Indeed, while there have been enormous advances in our understanding of the basic biological processes contributing to many human diseases, a detailed understanding of the processes underlying schizophrenia and other complex mental disorders remains elusive. With the sequencing of the human genome and the development of genomics-based technologies, there are unprecedented opportunities for gaining fundamental new insights into these complex diseases<sup>150</sup>. Currently, at least three highly-overlapping hypotheses of the underlying pathophysiology of schizophrenia drive drug discovery efforts<sup>16</sup>.

The first hypothesis, and the one that accounts for all of the current antipsychotic medications and the vast majority of compounds in the pipeline, is the ***signal***

**transduction hypothesis** that posits that basic alterations in receptor-mediated signal transduction induces schizophrenia-like psychopathology. Therefore, normalizing the altered signaling with medications targeting receptor and post-receptor molecules should be efficacious in treating schizophrenia<sup>116,151</sup>. Indeed, targeting these neurotransmitter receptors sites has, to this point, been the predominate focus of psychopharmacological research, and this strategy has led to significant advances in our understanding of the pathophysiology of schizophrenia and brain function as a whole. Future efforts, however, should move beyond the current strategies of solely targeting the synaptic neurotransmission at the receptor level to the development of agents that can affect more diverse cellular functions including intracellular signaling pathways and the mechanisms involved in synaptic plasticity.

Secondly, **the molecular-genetic hypothesis** posits that it is strong effects of susceptibility genes underlying the pathophysiology of schizophrenia<sup>152</sup>, and suggests that targeting drugs at these genes or their associated anatomic and functional pathways might yield novel and more effective treatments for schizophrenia<sup>153,154</sup>. Indeed, significant progress has been made in recent years on elucidating various susceptibility genes in schizophrenia, including dysbindin, neuregulin 1, COMT, DISC1 and others<sup>155</sup>. Interestingly, many of these genes appear to be related to the control of synaptic plasticity and glutamate transmission (particularly NMDA receptor function). These recent breakthroughs in genetic studies of schizophrenia begin to allow for hypothesis-driven approaches for developing of actual disease-modifying drugs for

schizophrenia. In addition, individualized treatment strategies could be developed that are focused on subgroups of schizophrenia patients with specific susceptibility alleles.

A third hypothesis, ***the neural network hypothesis***, proposes that schizophrenia results from the strong effects of altered neuronal integration. Thus, this hypothesis predicts that drugs that fundamentally reset the tone of networks of neuronal interactions will prove efficacious in treating schizophrenia<sup>149,156</sup>. Indeed, significant evidence exists suggesting that schizophrenia is a neurodevelopmental disorder associated with abnormal connectivity resulting from defects in synaptic pruning and migration of neurons<sup>157</sup>. Thus, if alterations in synaptic pruning are the primary process underlying the pathophysiology of schizophrenia, possibly due to inherited genetic alterations in genes such as DISC1 or dysbindin, then effective treatment strategies should target the underlying deficits **[Figure1 - Synapse]**. In addition, successful treatment of schizophrenia may then require early recognition and treatment during or even before an obvious prodromal stage. However, if the underlying defects are due to abnormal migration of cortical neurons and subsequent dysregulation of cortical development, it may be impossible to ameliorate such deficits via simple pharmacological approaches.

### *Challenges of future drug discovery*

While there has been significant progress in our understanding of the underlying pathophysiology of schizophrenia, a great deal of additional research is needed before

we can begin the systematic development of drugs that may address the root cause of the disease. Thus, before our full understanding of those causes, the development of novel drugs with superior efficacy and improved side effect profiles is still essential. It has been suggested that “selectively non-selective” drugs, or “magic shotguns,” can already be developed and may fill a clinical need for improved therapeutics<sup>31,44</sup>. Indeed, genomics-based screening approaches are being used to identify novel drug candidates based on their ability to either mimic the gene expression “signature” of gold-standard drugs like clozapine, or based on their ability to normalize the expression of genes that are altered in schizophrenia<sup>45</sup>. Alternatively, high-throughput behavioral screenings may prove useful for the identification of novel medications for schizophrenia<sup>45</sup>, though hurdles exist in finding animal behavioral models with good predictive value. This lack of predictive, reliable and efficient animal models has severely hindered progress in discovering novel therapeutics for schizophrenia, highlighting a need for increased collaboration between scientists in academic settings and industry.

Indeed, the translation of newly gained knowledge into fundamentally new therapeutics is a major challenge facing the biomedical research community. Fiscal pressures that govern research efforts in industry make it increasingly difficult for companies to invest significant resources in exploratory projects and basic research that capitalize on translating discoveries of basic science into marketable products. Because of this, companies frequently launch expensive drug discovery and development programs based on intriguing but often poorly validated targets for novel therapeutic approaches. For the treatment of schizophrenia, for example, preclinical

models are highly effective at predicting whether or not a candidate molecule would have 'atypical' properties, but are only fair at predicting overall efficacy and are ineffective at predicting efficacy greater than 'conventional treatment'. In addition, none of the available animals models accurately predicts the propensity of various antipsychotic drugs to induce weight gain and associated side-effects, although some of this can be predicted based on a knowledge of *in vitro* receptor pharmacology<sup>158</sup>. Moreover, in terms of the negative and cognitive symptom domains in schizophrenia, none of the commonly used animal models are highly predictive, although preclinical memory models may be useful for predicting ability to enhance cognition. Thus, we advocate that academic-based scientists should be more aggressively involved in contributing to the drug discovery process, particularly by focusing on target validation<sup>15</sup> **[Figure 2 - Validation]**. This challenge will require increased collaboration with the pharmaceutical industry as well as priority by the NIMH to fund such endeavors.

## Conclusions

In the past 20 years, new therapies for schizophrenia have primarily emerged from a quest to discover new drugs that lack the extrapyramidal side effects of the typical antipsychotic drugs. Indeed, the atypicals have been beneficial to patients due to their improved therapeutic margin and their somewhat better efficacy at treating the negative symptoms of schizophrenia. However, the atypicals have significant side effect profiles as well, including weight gain and diabetes—likely due to off-target

actions at therapeutically irrelevant receptors<sup>158,159</sup>. Thus, we have reached a significant bottleneck in the drug discovery process due to incomplete understanding of the mechanisms of action of the currently available antipsychotics as well as poorly defined pathophysiology for this complex and likely heterogeneous disorder. Interestingly, as many of the atypicals will soon go off patent, there is increased urgency within the pharmaceutical industry to develop new, novel treatments for schizophrenia.

We predict that the future of pharmacologic treatment of schizophrenia will likely start with the continued use of polypharmacy and augmentation strategies aimed at treating the multiple symptom domains of schizophrenia. This may be followed by the development of selectively-nonspecific single compounds that can target multiple domains at once while simultaneously decreasing side effects, eliminating potential pharmacokinetic interactions and improving medication compliance<sup>31,45</sup>. The long-term goal, of course, will be to develop “cure therapeutics”<sup>154</sup> which will likely require a substantial shift in the current paradigm of drug development and significant advances in our understanding of the pathophysiology of schizophrenia. Thus, it is important to continue pursue diverse molecular targets and increase efforts at validating novel targets. Indeed, recent breakthroughs in genetic studies of schizophrenia have provided renewed excitement that novel targets for the development that may target underlying disease processes. This shift in our approach to drug development will require considerable contributions from academic-based researchers as well as bold and potentially risky endeavors by the pharmaceutical industry.

## References

1. Labhardt F. [Largactil therapy in schizophrenia and other psychotic conditions.]. Schweiz Arch Neurol Psychiatr 1954; 73:309-38.
2. Murphy BP, Chung YC, Park TW, McGorry PD. Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review. Schizophr Res 2006; 88:5-25.
3. Kane J, Honigfeld G, Singer J, Meltzer HY. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45:789-96.
4. Meltzer HY, Alphs L, Green AI, et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 2003; 60:82-91.
5. Bilder RM, Goldman RS, Volavka J, et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry 2002; 159:1018-28.
6. Lindstrom LH. The effect of long-term treatment with clozapine in schizophrenia: a retrospective study in 96 patients treated with clozapine for up to 13 years. Acta Psychiatr Scand 1988; 77:524-9.
7. McEvoy JP, Lieberman JA, Stroup TS, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006; 163:600-10.
8. Fleischhacker WW. New drugs for the treatment of schizophrenic patients. Acta Psychiatr Scand Suppl 1995; 388:24-30.
9. Swartz MS, Perkins DO, Stroup TS, et al. Effects of Antipsychotic Medications on Psychosocial Functioning in Patients With Chronic Schizophrenia: Findings From the NIMH CATIE Study. Am J Psychiatry 2007; 164:428-36.
10. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353:1209-23.
11. Keefe RS, Silva SG, Perkins DO, Lieberman JA. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr Bull 1999; 25:201-22.



12. Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. *Schizophr Res* 1999; 35:51-68.
13. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. *Am J Psychiatry* 1999; 156:1686-96.
14. Newcomer JW, Haupt DW, Fucetola R, et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. *Arch Gen Psychiatry* 2002; 59:337-45.
15. Kozikowski AP, Roth B, Tropsha A. Why academic drug discovery makes sense. *Science* 2006; 313:1235-6.
16. Roth BL. Contributions of molecular biology to antipsychotic drug discovery: promises fulfilled or unfulfilled? *Dialogues Clin Neurosci* 2006; 8:303-9.
17. Kane J, Canas F, Kramer M, et al. Treatment of schizophrenia with paliperidone extended-release tablets: A 6-week placebo-controlled trial. *Schizophr Res* 2007; 90:147-61.
18. Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. *Methods Find Exp Clin Pharmacol* 2006; 28:185-206.
19. O'Connor KA, Roth BL. Finding new tricks for old drugs: an efficient route for public-sector drug discovery. *Nat Rev Drug Discov* 2005; 4:1005-14.
20. Hyman SE, Fenton WS. Medicine. What are the right targets for psychopharmacology? *Science* 2003; 299:350-1.
21. Agid Y, Buzsaki G, Diamond DM, et al. How can drug discovery for psychiatric disorders be improved? *Nat Rev Drug Discov* 2007; 6:189-201.
22. Norman RM, Malla AK, McLean T, et al. The relationship of symptoms and level of functioning in schizophrenia to general wellbeing and the Quality of Life Scale. *Acta Psychiatr Scand* 2000; 102:303-9.
23. Katschnig H. Schizophrenia and quality of life. *Acta Psychiatr Scand Suppl* 2000:33-7.
24. Kirkpatrick B, Fenton WS, Carpenter WT, Jr., Marder SR. The NIMH-MATRICES consensus statement on negative symptoms. *Schizophr Bull* 2006; 32:214-9.
25. Keefe RS, Bilder RM, Harvey PD, et al. Baseline neurocognitive deficits in the CATIE schizophrenia trial. *Neuropsychopharmacology* 2006; 31:2033-46.

26. Bowie CR, Harvey PD. Cognition in schizophrenia: impairments, determinants, and functional importance. *Psychiatr Clin North Am* 2005; 28:613-33, 626.
27. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? *Am J Psychiatry* 1996; 153:321-30.
28. Purdon SE, Jones BD, Stip E, et al. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia. *Arch Gen Psychiatry* 2000; 57:249-58.
29. Harvey PD, Keefe RS. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. *Am J Psychiatry* 2001; 158:176-84.
30. Marder SR, Fenton W. Measurement and Treatment Research to Improve Cognition in Schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia. *Schizophr Res* 2004; 72:5-9.
31. Roth BL, Sheffler DJ, Kroeze WK. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. *Nat Rev Drug Discov* 2004; 3:353-9.
32. Davies MA, Sheffler DJ, Roth BL. Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology. *CNS Drug Rev* 2004; 10:317-36.
33. Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. *Science* 1976; 192:481-3.
34. Seeman P, Chau-Wong M, Tedesco J, Wong K. Dopamine receptors in human and calf brains, using [<sup>3</sup>H]apomorphine and an antipsychotic drug. *Proc Natl Acad Sci U S A* 1976; 73:4354-8.
35. Nordstrom AL, Farde L, Wiesel FA, et al. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. *Biol Psychiatry* 1993; 33:227-35.
36. Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. *Arch Gen Psychiatry* 1992; 49:538-44.

37. Meltzer HY. Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. *Psychopharmacology (Berl)* 1989; 99 Suppl:S18-27.
38. Shapiro DA, Renock S, Arrington E, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. *Neuropsychopharmacology* 2003; 28:1400-11.
39. Yokoi F, Grunder G, Biziere K, et al. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [<sup>11</sup>C]raclopride. *Neuropsychopharmacology* 2002; 27:248-59.
40. Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. *Mol Psychiatry* 2005; 10:79-104.
41. Burstein ES, Ma J, Wong S, et al. Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylozapine as a D2/D3 partial agonist. *J Pharmacol Exp Ther* 2005; 315:1278-87.
42. Davies MA, Compton-Toth BA, Hufeisen SJ, Meltzer HY, Roth BL. The highly efficacious actions of N-desmethylozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: is M1 agonism a prerequisite for mimicking clozapine's actions? *Psychopharmacology (Berl)* 2005; 178:451-60.
43. Weiner DM, Meltzer HY, Veinbergs I, et al. The role of M1 muscarinic receptor agonism of N-desmethylozapine in the unique clinical effects of clozapine. *Psychopharmacology (Berl)* 2004; 177:207-16.
44. Sams-Dodd F. Target-based drug discovery: is something wrong? *Drug Discov Today* 2005; 10:139-47.
45. Gray JA, Roth BL. Developing selectively nonselective drugs for treating CNS disorders. *Drug Discovery Today: Therapeutic Strategies* 2006; 3:413-419.

46. Goldman-Rakic PS, Castner SA, Svensson TH, Siever LJ, Williams GV. Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction. *Psychopharmacology (Berl)* 2004; 174:3-16.
47. Okubo Y, Suhara T, Suzuki K, et al. Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. *Nature* 1997; 385:634-6.
48. Castner SA, Williams GV, Goldman-Rakic PS. Reversal of antipsychotic-induced working memory deficits by short-term dopamine D1 receptor stimulation. *Science* 2000; 287:2020-2.
49. Karlsson P, Smith L, Farde L, Harnryd C, Sedvall G, Wiesel FA. Lack of apparent antipsychotic effect of the D1-dopamine receptor antagonist SCH39166 in acutely ill schizophrenic patients. *Psychopharmacology (Berl)* 1995; 121:309-16.
50. Den Boer JA, van Megen HJ, Fleischhacker WW, et al. Differential effects of the D1-DA receptor antagonist SCH39166 on positive and negative symptoms of schizophrenia. *Psychopharmacology (Berl)* 1995; 121:317-22.
51. Cai JX, Arnsten AF. Dose-dependent effects of the dopamine D1 receptor agonists A77636 or SKF81297 on spatial working memory in aged monkeys. *J Pharmacol Exp Ther* 1997; 283:183-9.
52. Arnsten AF, Cai JX, Murphy BL, Goldman-Rakic PS. Dopamine D1 receptor mechanisms in the cognitive performance of young adult and aged monkeys. *Psychopharmacology (Berl)* 1994; 116:143-51.
53. Williams GV, Goldman-Rakic PS. Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. *Nature* 1995; 376:572-5.
54. Castner SA, Goldman-Rakic PS. Enhancement of working memory in aged monkeys by a sensitizing regimen of dopamine D1 receptor stimulation. *J Neurosci* 2004; 24:1446-50.
55. Joyce JN, Millan MJ. Dopamine D3 receptor antagonists as therapeutic agents. *Drug Discov Today* 2005; 10:917-25.
56. Gurevich EV, Bordelon Y, Shapiro RM, Arnold SE, Gur RE, Joyce JN. Mesolimbic dopamine D3 receptors and use of antipsychotics in patients with schizophrenia. A postmortem study. *Arch Gen Psychiatry* 1997; 54:225-32.
57. Witkin J, Gasior M, Acri J, et al. Atypical antipsychotic-like effects of the dopamine D3 receptor agonist, (+)-PD 128,907. *Eur J Pharmacol* 1998; 347:R1-3.

58. Vonderfecht SL, Stone ML, Eversole RR, et al. Myopathy related to administration of a cationic amphiphilic drug and the use of multidose drug distribution analysis to predict its occurrence. *Toxicol Pathol* 2004; 32:318-25.
59. Hackling AE, Stark H. Dopamine D3 receptor ligands with antagonist properties. *Chembiochem* 2002; 3:946-61.
60. Reavill C, Taylor SG, Wood MD, et al. Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A. *J Pharmacol Exp Ther* 2000; 294:1154-65.
61. Laszy J, Laszlovszky I, Gyertyan I. Dopamine D3 receptor antagonists improve the learning performance in memory-impaired rats. *Psychopharmacology (Berl)* 2005; 179:567-75.
62. Van Tol HH, Bunzow JR, Guan HC, et al. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. *Nature* 1991; 350:610-4.
63. Tarazi FI, Zhang K, Baldessarini RJ. Dopamine D4 receptors: beyond schizophrenia. *J Recept Signal Transduct Res* 2004; 24:131-47.
64. Kramer MS, Last B, Getson A, Reines SA. The effects of a selective D4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia. D4 Dopamine Antagonist Group. *Arch Gen Psychiatry* 1997; 54:567-72.
65. Corrigan MH, Gallen CC, Bonura ML, Merchant KM. Effectiveness of the selective D4 antagonist sonepiprazole in schizophrenia: a placebo-controlled trial. *Biol Psychiatry* 2004; 55:445-51.
66. Truffinet P, Tamminga CA, Fabre LF, Meltzer HY, Riviere ME, Papillon-Downey C. Placebo-controlled study of the D4/5-HT2A antagonist fananserin in the treatment of schizophrenia. *Am J Psychiatry* 1999; 156:419-25.
67. Kotecha SA, Oak JN, Jackson MF, et al. A D2 class dopamine receptor transactivates a receptor tyrosine kinase to inhibit NMDA receptor transmission. *Neuron* 2002; 35:1111-22.
68. Rubinstein M, Cepeda C, Hurst RS, et al. Dopamine D4 receptor-deficient mice display cortical hyperexcitability. *J Neurosci* 2001; 21:3756-63.

69. Jentsch JD, Taylor JR, Redmond DE, Jr., Elsworth JD, Youngren KD, Roth RH. Dopamine D4 receptor antagonist reversal of subchronic phencyclidine-induced object retrieval/detour deficits in monkeys. *Psychopharmacology (Berl)* 1999; 142:78-84.
70. Tunbridge EM, Harrison PJ, Weinberger DR. Catechol-o-methyltransferase, cognition, and psychosis: Val158Met and beyond. *Biol Psychiatry* 2006; 60:141-51.
71. Kopin IJ. Catecholamine metabolism: basic aspects and clinical significance. *Pharmacol Rev* 1985; 37:333-64.
72. Karoum F, Chrapusta SJ, Egan MF. 3-Methoxytyramine is the major metabolite of released dopamine in the rat frontal cortex: reassessment of the effects of antipsychotics on the dynamics of dopamine release and metabolism in the frontal cortex, nucleus accumbens, and striatum by a simple two pool model. *J Neurochem* 1994; 63:972-9.
73. Gogos JA, Morgan M, Luine V, et al. Catechol-O-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior. *Proc Natl Acad Sci U S A* 1998; 95:9991-6.
74. Liljequist R, Haapalinna A, Ahlander M, Li YH, Mannisto PT. Catechol O-methyltransferase inhibitor tolcapone has minor influence on performance in experimental memory models in rats. *Behav Brain Res* 1997; 82:195-202.
75. Gasparini M, Fabrizio E, Bonifati V, Meco G. Cognitive improvement during Tolcapone treatment in Parkinson's disease. *J Neural Transm* 1997; 104:887-94.
76. Watkins P. COMT inhibitors and liver toxicity. *Neurology* 2000; 55:S51-2; discussion S53-6.
77. Chen J, Lipska BK, Halim N, et al. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. *Am J Hum Genet* 2004; 75:807-21.
78. Woodward ND, Jayathilake K, Meltzer HY. COMT val108/158met genotype, cognitive function, and cognitive improvement with clozapine in schizophrenia. *Schizophr Res* 2007; 90:86-96.
79. Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. *J Pharmacol Exp Ther* 1989; 251:238-46.

80. Altar CA, Wasley AM, Neale RF, Stone GA. Typical and atypical antipsychotic occupancy of D2 and S2 receptors: an autoradiographic analysis in rat brain. *Brain Res Bull* 1986; 16:517-25.
81. de Paulis T. M-100907 (Aventis). *Curr Opin Investig Drugs* 2001; 2:123-32.
82. Meltzer HY, Arvanitis L, Bauer D, Rein W. Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. *Am J Psychiatry* 2004; 161:975-84.
83. Nocjar C, Roth BL, Pehek EA. Localization of 5-HT(2A) receptors on dopamine cells in subnuclei of the midbrain A10 cell group. *Neuroscience* 2002; 111:163-76.
84. Alex KD, Pehek EA. Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. *Pharmacol Ther* 2007; 113:296-320.
85. Meltzer HY. Pre-clinical pharmacology of atypical antipsychotic drugs: a selective review. *Br J Psychiatry Suppl* 1996:23-31.
86. Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. *Eur J Pharmacol* 2002; 441:137-40.
87. Ichikawa J, Ishii H, Bonaccorso S, Fowler WL, O'Laughlin IA, Meltzer HY. 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. *J Neurochem* 2001; 76:1521-31.
88. Roth BL, Hanizavareh SM, Blum AE. Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders. *Psychopharmacology (Berl)* 2004; 174:17-24.
89. Reynolds GP, Mason SL, Meldrum A, et al. 5-Hydroxytryptamine (5-HT)<sub>4</sub> receptors in post mortem human brain tissue: distribution, pharmacology and effects of neurodegenerative diseases. *Br J Pharmacol* 1995; 114:993-8.
90. Cho S, Hu Y. Activation of 5-HT<sub>4</sub> receptors inhibits secretion of beta-amyloid peptides and increases neuronal survival. *Exp Neurol* 2007; 203:274-8.
91. Roth BL, Craigo SC, Choudhary MS, et al. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. *J Pharmacol Exp Ther* 1994; 268:1403-10.

92. Mitchell ES, Neumaier JF. 5-HT<sub>6</sub> receptors: a novel target for cognitive enhancement. *Pharmacol Ther* 2005; 108:320-33.
93. Bourson A, Boess FG, Bos M, Sleight AJ. Involvement of 5-HT<sub>6</sub> receptors in nigro-striatal function in rodents. *Br J Pharmacol* 1998; 125:1562-6.
94. Rogers DC, Robinson CA, Quilter AJ, Hunter C, Routledge C, Hagan JJ. Cognitive enhancement effects of the selective 5-HT<sub>6</sub> antagonist SB-271046. *Br J Pharmacol Suppl* 1999; 127:22.
95. Coull JT. Pharmacological manipulations of the alpha 2-noradrenergic system. Effects on cognition. *Drugs Aging* 1994; 5:116-26.
96. Fields RB, Van Kammen DP, Peters JL, et al. Clonidine improves memory function in schizophrenia independently from change in psychosis. Preliminary findings. *Schizophr Res* 1988; 1:417-23.
97. Friedman JI, Adler DN, Temporini HD, et al. Guanfacine treatment of cognitive impairment in schizophrenia. *Neuropsychopharmacology* 2001; 25:402-9.
98. Millan MJ, Gobert A, Newman-Tancredi A, et al. S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: I. Receptorial, neurochemical, and electrophysiological profile. *J Pharmacol Exp Ther* 2000; 292:38-53.
99. Gobert A, Rivet JM, Audinot V, Newman-Tancredi A, Cistarelli L, Millan MJ. Simultaneous quantification of serotonin, dopamine and noradrenaline levels in single frontal cortex dialysates of freely-moving rats reveals a complex pattern of reciprocal auto- and heteroreceptor-mediated control of release. *Neuroscience* 1998; 84:413-29.
100. Litman RE, Su TP, Potter WZ, Hong WW, Pickar D. Idazoxan and response to typical neuroleptics in treatment-resistant schizophrenia. Comparison with the atypical neuroleptic, clozapine. *Br J Psychiatry* 1996; 168:571-9.
101. Sarter M, Bruno JP. Cognitive functions of cortical acetylcholine: toward a unifying hypothesis. *Brain Res Brain Res Rev* 1997; 23:28-46.
102. Friedman JI. Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists. *Psychopharmacology (Berl)* 2004; 174:45-53.



103. Birks J. Cholinesterase inhibitors for Alzheimer's disease. *Cochrane Database Syst Rev* 2006:CD005593.
104. Friedman JI, Temporini H, Davis KL. Pharmacologic strategies for augmenting cognitive performance in schizophrenia. *Biol Psychiatry* 1999; 45:1-16.
105. Ferreri F, Agbokou C, Gauthier S. Cognitive dysfunctions in schizophrenia: potential benefits of cholinesterase inhibitor adjunctive therapy. *J Psychiatry Neurosci* 2006; 31:369-76.
106. Raedler TJ, Bymaster FP, Tandon R, Copolov D, Dean B. Towards a muscarinic hypothesis of schizophrenia. *Mol Psychiatry* 2006.
107. Bymaster FP, Felder C, Ahmed S, McKinzie D. Muscarinic receptors as a target for drugs treating schizophrenia. *Curr Drug Targets CNS Neurol Disord* 2002; 1:163-81.
108. Sur C, Mallorga PJ, Wittmann M, et al. N-desmethylozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-D-aspartate receptor activity. *Proc Natl Acad Sci U S A* 2003; 100:13674-9.
109. Watson J, Brough S, Coldwell MC, et al. Functional effects of the muscarinic receptor agonist, xanomeline, at 5-HT1 and 5-HT2 receptors. *Br J Pharmacol* 1998; 125:1413-20.
110. Mirza NR, Peters D, Sparks RG. Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists. *CNS Drug Rev* 2003; 9:159-86.
111. Kumari V, Postma P. Nicotine use in schizophrenia: the self medication hypotheses. *Neurosci Biobehav Rev* 2005; 29:1021-34.
112. Simosky JK, Stevens KE, Freedman R. Nicotinic agonists and psychosis. *Curr Drug Targets CNS Neurol Disord* 2002; 1:149-62.
113. Simosky JK, Stevens KE, Kem WR, Freedman R. Intragastric DMXB-A, an alpha7 nicotinic agonist, improves deficient sensory inhibition in DBA/2 mice. *Biol Psychiatry* 2001; 50:493-500.
114. Olincy A, Harris JG, Johnson LL, et al. Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. *Arch Gen Psychiatry* 2006; 63:630-8.
115. Levin ED, McClernon FJ, Rezvani AH. Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization. *Psychopharmacology (Berl)* 2006; 184:523-39.

116. Javitt DC. Glutamate as a therapeutic target in psychiatric disorders. *Mol Psychiatry* 2004; 9:984-97, 979.
117. Javitt DC. Is the glycine site half saturated or half unsaturated? Effects of glutamatergic drugs in schizophrenia patients. *Curr Opin Psychiatry* 2006; 19:151-7.
118. Evins AE, Fitzgerald SM, Wine L, Rosselli R, Goff DC. Placebo-controlled trial of glycine added to clozapine in schizophrenia. *Am J Psychiatry* 2000; 157:826-8.
119. Tsai GE, Yang P, Chung LC, Tsai IC, Tsai CW, Coyle JT. D-serine added to clozapine for the treatment of schizophrenia. *Am J Psychiatry* 1999; 156:1822-5.
120. Goff DC, Tsai G, Manoach DS, Flood J, Darby DG, Coyle JT. D-cycloserine added to clozapine for patients with schizophrenia. *Am J Psychiatry* 1996; 153:1628-30.
121. Brown A, Carlyle I, Clark J, et al. Discovery and SAR of org 24598-a selective glycine uptake inhibitor. *Bioorg Med Chem Lett* 2001; 11:2007-9.
122. Aubrey KR, Vandenberg RJ. N[3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)propyl]sarcosine (NFPS) is a selective persistent inhibitor of glycine transport. *Br J Pharmacol* 2001; 134:1429-36.
123. Tsai G, Lane HY, Yang P, Chong MY, Lange N. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. *Biol Psychiatry* 2004; 55:452-6.
124. Lane HY, Huang CL, Wu PL, et al. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia. *Biol Psychiatry* 2006; 60:645-9.
125. Moghaddam B. Targeting metabotropic glutamate receptors for treatment of the cognitive symptoms of schizophrenia. *Psychopharmacology (Berl)* 2004; 174:39-44.
126. Galici R, Jones CK, Hemstapat K, et al. Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in mice. *J Pharmacol Exp Ther* 2006; 318:173-85.
127. Govek SP, Bonnefous C, Hutchinson JH, et al. Benzazoles as allosteric potentiators of metabotropic glutamate receptor 2 (mGluR2): efficacy in an animal model for schizophrenia. *Bioorg Med Chem Lett* 2005; 15:4068-72.
128. Marino MJ, Conn PJ. Glutamate-based therapeutic approaches: allosteric modulators of metabotropic glutamate receptors. *Curr Opin Pharmacol* 2006; 6:98-102.

129. Black MD. Therapeutic potential of positive AMPA modulators and their relationship to AMPA receptor subunits. A review of preclinical data. *Psychopharmacology (Berl)* 2005; 179:154-63.
130. Moghaddam B, Adams B, Verma A, Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. *J Neurosci* 1997; 17:2921-7.
131. Goff DC, Leahy L, Berman I, et al. A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia. *J Clin Psychopharmacol* 2001; 21:484-7.
132. Marenco S, Egan MF, Goldberg TE, et al. Preliminary experience with an ampakine (CX516) as a single agent for the treatment of schizophrenia: a case series. *Schizophr Res* 2002; 57:221-6.
133. Henquet C, Murray R, Linszen D, van Os J. The environment and schizophrenia: the role of cannabis use. *Schizophr Bull* 2005; 31:608-12.
134. Vinod KY, Hungund BL. Cannabinoid-1 receptor: a novel target for the treatment of neuropsychiatric disorders. *Expert Opin Ther Targets* 2006; 10:203-10.
135. Poncelet M, Barnouin MC, Breliere JC, Le Fur G, Soubrie P. Blockade of cannabinoid (CB1) receptors by 141716 selectively antagonizes drug-induced reinstatement of exploratory behaviour in gerbils. *Psychopharmacology (Berl)* 1999; 144:144-50.
136. Alonso R, Voutsinos B, Fournier M, et al. Blockade of cannabinoid receptors by SR141716 selectively increases Fos expression in rat mesocorticolimbic areas via reduced dopamine D2 function. *Neuroscience* 1999; 91:607-20.
137. Husum H, Vasquez PA, Mathe AA. Changed concentrations of tachykinins and neuropeptide Y in brain of a rat model of depression: lithium treatment normalizes tachykinins. *Neuropsychopharmacology* 2001; 24:183-91.
138. Kramer MS, Cutler N, Feighner J, et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. *Science* 1998; 281:1640-5.
139. Tooney PA, Crawter VC, Chahl LA. Increased tachykinin NK(1) receptor immunoreactivity in the prefrontal cortex in schizophrenia. *Biol Psychiatry* 2001; 49:523-7.

140. Keller M, Montgomery S, Ball W, et al. Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder. *Biol Psychiatry* 2006; 59:216-23.
141. Meltzer H, Prus A. NK3 receptor antagonists for the treatment of schizophrenia. *Drug Discovery Today: Therapeutic Strategies* 2006; 3:555-560.
142. Caceda R, Kinkead B, Nemeroff CB. Neurotensin: role in psychiatric and neurological diseases. *Peptides* 2006; 27:2385-404.
143. Feifel D, Reza TL, Wustrow DJ, Davis MD. Novel antipsychotic-like effects on prepulse inhibition of startle produced by a neurotensin agonist. *J Pharmacol Exp Ther* 1999; 288:710-3.
144. Riedel M, Strassnig M, Schwarz MJ, Muller N. COX-2 inhibitors as adjunctive therapy in schizophrenia: rationale for use and evidence to date. *CNS Drugs* 2005; 19:805-19.
145. Muller N, Ulmschneider M, Scheppach C, et al. COX-2 inhibition as a treatment approach in schizophrenia: immunological considerations and clinical effects of celecoxib add-on therapy. *Eur Arch Psychiatry Clin Neurosci* 2004; 254:14-22.
146. Menniti FS, Chappie TA, Humphrey JM, Schmidt CJ. Phosphodiesterase 10A inhibitors: a novel approach to the treatment of the symptoms of schizophrenia. *Curr Opin Investig Drugs* 2007; 8:54-9.
147. Sheitman BB, Knable MB, Jarskog LF, et al. Secretin for refractory schizophrenia. *Schizophr Res* 2004; 66:177-81.
148. Strous RD, Maayan R, Lapidus R, et al. Dehydroepiandrosterone augmentation in the management of negative, depressive, and anxiety symptoms in schizophrenia. *Arch Gen Psychiatry* 2003; 60:133-41.
149. Spedding M, Jay T, Costa e Silva J, Perret L. A pathophysiological paradigm for the therapy of psychiatric disease. *Nat Rev Drug Discov* 2005; 4:467-76.
150. Kelsoe JR. Genomics and the Human Genome Project: implications for psychiatry. *Int Rev Psychiatry* 2004; 16:294-300.
151. Carlsson M, Carlsson A. Schizophrenia: a subcortical neurotransmitter imbalance syndrome? *Schizophr Bull* 1990; 16:425-32.
152. Harrison PJ, Weinberger DR. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. *Mol Psychiatry* 2005; 10:40-68; image 5.

153. Sawa A, Snyder SH. Schizophrenia: neural mechanisms for novel therapies. *Mol Med* 2003; 9:3-9.
154. Insel TR, Scolnick EM. Cure therapeutics and strategic prevention: raising the bar for mental health research. *Mol Psychiatry* 2006; 11:11-7.
155. Ross CA, Margolis RL, Reading SA, Pletnikov M, Coyle JT. Neurobiology of schizophrenia. *Neuron* 2006; 52:139-53.
156. Hyman SE, Nestler EJ. Initiation and adaptation: a paradigm for understanding psychotropic drug action. *Am J Psychiatry* 1996; 153:151-62.
157. Rapoport JL, Addington AM, Frangou S, Psych MR. The neurodevelopmental model of schizophrenia: update 2005. *Mol Psychiatry* 2005; 10:434-49.
158. Kroeze WK, Hufeisen SJ, Popadak BA, et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. *Neuropsychopharmacology* 2003; 28:519-26.
159. Kim SF, Huang AS, Snowman AM, Teuscher C, Snyder SH. From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase 10.1073/pnas.0611417104. *PNAS* 2007; 104:3456-3459.

**Table 1.** Approximate<sup>a</sup> Pipeline of Drugs in Development for Schizophrenia

Primary Target Name <sup>b</sup>	Generic Name	Originator	World Status
<b>Launched<sup>c</sup></b>			
Multiple	clozapine	Novartis	Launched
D2, D3	nemonapride	Astellas	Launched
D2, 5-HT2A	olanzapine	Eli Lilly	Launched
D2, 5-HT2A	quetiapine	AstraZeneca	Launched
D2, 5-HT2A	risperidone	Johnson & Johnson	Launched
D2, 5-HT2A	paliperidone	Johnson & Johnson	Launched
D2, 5-HT2A	sertindole	Lundbeck	Launched
D2, 5-HT2A	ziprasidone	Pfizer	Launched
D2 partial, 5-HT1A agonist	aripiprazole	Otsuka	Launched
<b>Phase III</b>			
Multiple	asenapine	Organon/Pfizer	Discontinued by Pfizer <sup>d</sup>
D2 partial, 5-HT1A agonist	bifeprunox	Solvay	Phase III
D2, 5-HT2A	iloperidone	Titan Pharmaceuticals	Phase III
D2, 5-HT2A	blonanserin	Dainippon	Phase III
retinoid-X-receptor activator	bexarotene	Non-industry source	Phase III
<b>Phase II</b>			
Multiple	ACP-104 (NDMC <sup>e</sup> )	Acadia	Phase II
AMPA 1	Org-24448	Cortex Pharmaceuticals	Phase II
Unspecified	TGOF02N	Fabre-Kramer	Phase II
D2, 5-HT2A	ocaperidone	Johnson & Johnson	Phase II
α2AR, AChR agonist	dexefaroxan	Pierre Fabre	Phase II
Unspecified	uridine, Polifarma	Polifarma	Phase II
nischarin	idazoxan	Potomac Pharma	Phase II
NMDA allosteric modulator	D-serine	Prestwick Pharmaceuticals	Phase II
5-HT2A/2C	SR46349B	Sanofi-Aventis	Phase II
mGluR2	unknown	Eli Lilly	Phase II
NK3	osanetant	Sanofi-Aventis	Phase II
D2, 5-HT1A agonist	SLV-313	Solvay	Phase II
D2, 5HT transport inhibitor	SLV-310	Solvay	Phase II
D2, 5-HT2A	lurasidone hydrochloride	Sumitomo	Phase II
D2, D3 partial	aplindore fumarate	Wyeth	Phase II
sigma1 opioid	E-5842	Esteve	NDR <sup>f</sup>
D2 partial	(-)-3PPP, Maryland	Non-industrial source	NDR
D2 agonist, 5-HT1A	SDZ-MAR-327	Novartis	NDR
D2, 5-HT2A, 5-HT1A	abaperidone hydrochloride	Ferrer	NDR
D1, D2, 5-HT2A	ZD-3638	AstraZeneca	NDR
<b>Phase I</b>			
CB1	CBD cannabis derivative	GW Pharmaceuticals	Phase I
α7 nAChR	MEM-3454	Memory Pharmaceuticals	Phase I
Glycine Transporter	ALX-5407	NPS Pharmaceuticals	Phase I
Unspecified	YKP-1358	SK Corporation	Phase I
Unspecified	CRD-101	Curidium	Phase I
D3, 5-HT1A	BTS-79018	Abbott	NDR

D2, 5-HT1A	SSR-181507	Sanofi-Aventis	NDR
sigma1 opioid	SSR-125047	Sanofi-Aventis	NDR
D3	AVE-5997EF	Sanofi-Aventis	NDR
D4	NGD 94-1	Schering-Plough	NDR
<b>Preclinical</b>			
Glutamate antagonist	ADX-2 series	Addex	Preclinical
Glycine Transporter	GlyT-1 inhibitors, Organon	Akzo Nobel	Preclinical
Glycine Transporter	GlyT-1 inhibitors, Organon-2	Akzo Nobel	Preclinical
Glycine Transporter	GlyT-1 inhibitors, Organon-3	Akzo Nobel	Preclinical
Peptidergic receptor	ABS-201	Argolyn Bioscience	Preclinical
DA antagonist, GABA agonist	BL-1020	BioLineRx	Preclinical
Unspecified	BGC-20-761	BTG	Preclinical
Unspecified	GPCR allosteric modulators	Eli Lilly	Preclinical
D1	D1 agonist D2 antagonist	Eli Lilly	Preclinical
Unspecified	calcineurin modulators	Galenea	Preclinical
Unspecified	R-1678	Hoffmann-La Roche	Preclinical
Unspecified	schizophrenia therapy	Integragen	Preclinical
Unspecified	neuroleptics	Intra-Cellular Therapies	Preclinical
mGluR2	mGluR2 agonist	Merck & Co	Preclinical
$\alpha 7$ nAChR	RMG-40083	Remergent	Preclinical
Glycine Transporter	SSR-504734	Sanofi-Aventis	Preclinical
Glycine Transporter	SSR-103800	Sanofi-Aventis	Preclinical
Unspecified	schizophrenia therapy	Sequenom	Preclinical
Glycine Transporter	Org-24461	Servier	Preclinical
$\alpha 7$ nAChR	TC-5280	Targacept	Preclinical
D1	BSF-78438	Abbott	NDR
D2, 5-HT2A, mAChR	Org-23366	Akzo Nobel	NDR
D3	BP4.879a	Bioprojet	NDR
Unspecified	CDD-0304	Cognitive Pharmaceuticals	NDR
Unspecified	neuroleptics	CuraGen	NDR
neuregulin 1	schizophrenia therapy	deCODE genetics	NDR
sigma1 opioid	sigma antagonists	Esteve	NDR
D3	SB-277011	GlaxoSmithKline	NDR
5-HT4	5-HT4/D2 antagonists	Johnson & Johnson	NDR
Glycine Transporter	GlyT-1 inhlibs, Gliatech	Merck & Co	NDR
D1, D2, 5-HT2A	GMC-283	Merck KGaA	NDR
D2	Y-931	Mitsubishi Pharma	NDR
D2	dopamine antags	Neurogen Corporation	NDR
Unspecified	neuroleptic	Orion Pharma	NDR
D3	PD-157533	Pfizer	NDR
D3, D2	PD-157695	Pfizer	NDR
D2, 5-HT1A, D3	PD-158771	Pfizer	NDR
D4	PD-165167	Pfizer	NDR
D4	PD-172760	Pfizer	NDR
D3	U-99194A	Pfizer	NDR
D4	U-99363E	Pfizer	NDR
D3	PNU-177864	Pfizer	NDR
$\alpha 7$ nAChR	PNU-282987	Pfizer	NDR
Unspecified	clozapine-DHA, Protarga	Sankyo	NDR
D2, 5-HT, D4	HMR-2934	Sanofi-Aventis	NDR
Unspecified	P-1704	Sanofi-Aventis	NDR
D1	LE-300	Sanofi-Aventis	NDR
sigma1 opioid	MS-377	Schering AG	NDR
D4	SPI-376	Spectrum Pharmaceuticals	NDR

sigma1 opioid	NE-100	Taisho	NDR
mGluR	mGluR agonists	Taisho	NDR
α7 nAChR	TC-1698	Targacept	NDR
<b>Discontinued<sup>g</sup></b>			
D2, 5-HT2A, 5-HT1A agonist	1192U90	GlaxoSmithKline	Discontinued
D4	belaperidone	Abbott	Discontinued
sigma1 opioid	E-6276	Esteve	Discontinued
D3	RGH-1756	Gedeon Richter	Discontinued
sigma1 opioid	rimcazole	GlaxoSmithKline	Discontinued
Unspecified	EMD-66352	Merck KGaA	Discontinued
D2	SDZ-HDC-912	Novartis	Discontinued
D4	sonopiprazole	Pfizer	Discontinued
D2	(S)-amisulpride	Sanofi-Aventis	Discontinued
5-HT2A	fananserin	Sanofi-Aventis	Discontinued
sigma1 opioid	SR-31742A	Sanofi-Aventis	Discontinued
sigma1 opioid	MS-355	Schering AG	Discontinued
D2	remoxipride	AstraZeneca	Discontinued

<sup>a</sup>This is an approximation of the pipeline of drugs being developed for schizophrenia, adapted from BL Roth and PJ Conn: IOM White Paper, 2006. Attempts were made to make this table as accurate as possible, though due to the scarcity of published material the authors can accept no responsibility for the currency and accuracy of this table. Subsections of the table are in no particular order.

<sup>b</sup>Compounds are assumed to be antagonists at each listed target unless otherwise specified.

<sup>c</sup>Only includes the atypical antipsychotics

<sup>d</sup>Organon may be continuing development,

(<http://www.medicalnewstoday.com/medicalnews.php?newsid=57683>)

<sup>e</sup>NDMC, N-desmethylozapine

<sup>f</sup>NDR, no development reported, compounds are listed as to their last known Phase of development.

<sup>g</sup>Recently discontinued compounds



**Table 2.** Approximate  $K_i^a$  values (in nM) for selected current and pipeline antipsychotics

Receptor <sup>b</sup>	haloperidol	clozapine	N-DMC <sup>c</sup>	risperidone	paliperidone (9-OH- risperidone)	iloperidone	asenapine (Org-5222)
<b>D<sub>1</sub></b>	122	266	14	244	41	129	2.9
<b>D<sub>2</sub></b>	2.1	141	101	2.4	1.6	11	1.4
<b>D<sub>3</sub></b>	5.4	347	153	8	3.5	11	1.8
<b>D<sub>4</sub></b>	3.9	23	64	5.8	54	14	1.8
<b>D<sub>5</sub></b>	124	255	284	290	29	319	23
<b>5-HT<sub>1A</sub></b>	2067	134	14	423	617	93	32
<b>5-HT<sub>2A</sub></b>	83	9.3	11	0.34	1.1	1.9	0.28
<b>5-HT<sub>5A</sub></b>	2247	3857	351	206	278	N/A	4
<b>5-HT<sub>6</sub></b>	5133	13	12	2057	2414	63	1.4
<b>5-HT<sub>7</sub></b>	626	37	60	5.6	2.7	112	0.72
<b>α<sub>1A</sub></b>	12	1.6	105	5	2.5	N/A	4.4
<b>α<sub>2A</sub></b>	1932	90	138	151	3.9	162	8.5
<b>M<sub>1</sub></b>	>10000	14	68	>10000	>10000	4898	24
<b>M<sub>2</sub></b>	>10000	104	415	>10000	>10000	3311	79
<b>M<sub>3</sub></b>	>10000	32	96	>10000	>10000	>10000	39
<b>M<sub>4</sub></b>	>10000	18	170	>10000	>10000	8318	>10000
<b>M<sub>5</sub></b>	657	28	35	>10000	>10000	>1000	9.5
<b>H<sub>1</sub></b>	1698	1.3	3.4	20	19	12 <sup>c</sup>	0.16
<b>H<sub>2</sub></b>	1003	153	375	120	121	N/A	23

<sup>a</sup>Averaged from cloned human receptor data from the Psychoactive Drug Screening Program database (<http://pdsp.med.unc.edu/pdsp.php>), and references therein.

<sup>b</sup>Abbreviations: 5-HT (serotonin), D (dopamine), M (muscarinic acetylcholine), H (histamine), alpha (α-adrenergic)

<sup>c</sup>N-desmethylclozapine

<sup>d</sup>Cloned human receptor data not available, data from human brain tissue

**Table 3.** Possible Pharmacologic Targets in Schizophrenia

<b>Primary Symptom Domains</b>	<b>Potentially Druggable Clinical Targets</b>	<b>Possible Pharmacologic Targets</b>
Positive Symptoms	Hallucinations Delusions Formal Thought Disorder	Dopamine D <sub>2</sub> antagonists Dopamine D <sub>2</sub> partial agonists Dopamine D <sub>3</sub> antagonists/agonists Muscarinic M <sub>1</sub> agonists Glutamate modulators Cannabinoid CB <sub>1</sub> antagonists Neurokinin NK <sub>3</sub> antagonists Neurotensin NT1 agonists PDE10A inhibitors Glycine transport inhibitors mGluR2 positive modulators
Negative Symptoms	Blunted Affect Anhedonia Avolition Alogia Asociality	Dopamine D <sub>1</sub> agonists Dopamine D <sub>3</sub> antagonists/antagonists Serotonin 5-HT <sub>2A</sub> antagonists Serotonin 5-HT <sub>1A</sub> partial agonists NMDA modulators Glycine transport inhibitors Neurokinin NK <sub>3</sub> antagonists Neurosteroids
Cognitive Deficits	Working Memory Attention/Vigilance Verbal Learning/Memory Visual Learning/Memory Reasoning/Problem Solving Information Processing Speed Social Cognition	Dopamine D <sub>1</sub> agonists Dopamine D <sub>3</sub> agonists COMT inhibitors Serotonin 5-HT <sub>2A</sub> antagonists Serotonin 5-HT <sub>1A</sub> partial agonists Serotonin 5-HT <sub>4</sub> partial agonists Serotonin 5-HT <sub>6</sub> antagonists Cholinesterase inhibitors Muscarinic M <sub>1</sub> agonists Muscarinic M <sub>4</sub> agonists Nicotinic $\alpha$ 7 agonists and modulators Nicotinic $\alpha$ 4 $\beta$ 2 agonists NMDA positive modulators AMPA positive modulators Glycine transport inhibitors mGluR2/3 positive modulators GABA <sub>A</sub> positive modulators Neurokinin NK <sub>3</sub> antagonists COX2 inhibitors

## Figure Legends

*Figure 1.* Hypothetical Roles of Schizophrenia Genes at a Glutamatergic Synapse. Pictured is a hypothetical schematic of various putative schizophrenia susceptibility gene products and how they may affect neurotransmitter signaling at a glutamatergic synapse. The schizophrenia genes include: DISC-1 (disrupted in schizophrenia-1), Dysbindin, NRG1 (neuregulin-1), RGS4 (regulator of G protein signaling 4), COMT (catechol-*O*-methyltransferase), PDE4B (phosphodiesterase 4B), G72, and DAAO (D-amino acid oxidase). Other abbreviations are: Glu (glutamate), DA (dopamine), NMDA (*N*-methyl-D-aspartate glutamate receptor), 5-HT<sub>2A</sub> (serotonin receptor 2A), mGluR5 (metabotropic glutamate receptor 5), D<sub>1</sub> (dopamine receptor 1), ErbB4 (ErbB-type tyrosine kinase receptor B4), cAMP (cyclic adenosine monophosphate), G<sub>q</sub>/G<sub>s</sub> (G proteins), PSD95 (postsynaptic density protein 95), D-ser (D-serine). Adapted from Harrison and Weinberger<sup>152</sup> and Roth<sup>16</sup>.

*Figure 2.* Continuous Target Validation in Academia. Identifying and validating novel targets is a significant rate-limiting step in new drug development which has led to few new drugs with truly novel mechanisms of action. Translation of newly gained knowledge into fundamentally new therapeutics is a major challenge facing the biomedical research community and is limited by fiscal pressures governing research efforts in industry that make it difficult for companies to invest significant resources on risky exploratory projects and basic research. Thus, increased research in the academic setting is needed to identify selective compounds for novel targets that may

be used for testing hypotheses at these targets and for proof of concept experiments.

Continuous validation of targets by academic scientists at each step in the drug development process, including proof of concept experiments in the clinical setting, may facilitate the development of fundamentally new therapeutics for schizophrenia.

Adapted from BL Roth and PJ Conn: IOM White Paper, 2006.



